Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: NCT05681598 Clinical Landscape Report 2026
15 October 2026
NCT05681598 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ZSP-1601 in Metabolic Dysfunction Associated Steatohepatitis: NCT05692492 Clinical Landscape Report 2026
15 October 2026
NCT05692492 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Coagulation factor VIIa (recombinant)-jncw(LFB Biotechnologies SASU) in Hemorrhage: NCT05695391 Clinical Landscape Report 2026
15 October 2026
NCT05695391 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dalnacogene ponparvovec in Hemophilia B: NCT05709288 Clinical Landscape Report 2026
15 October 2026
NCT05709288 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rurioctocog alfa pegol in Hemorrhage: NCT05707351 Clinical Landscape Report 2026
15 October 2026
NCT05707351 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluvoxamine Maleate in Metabolic Dysfunction Associated Steatohepatitis: NCT05712265 Clinical Landscape Report 2026
15 October 2026
NCT05712265 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Osivelotor in Anemia, Sickle Cell: NCT05718687 Clinical Landscape Report 2026
15 October 2026
NCT05718687 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tocilizumab in Myasthenia Gravis: NCT05716035 Clinical Landscape Report 2026
15 October 2026
NCT05716035 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etonogestrel in Anemia, Sickle Cell: NCT05730205 Clinical Landscape Report 2026
15 October 2026
NCT05730205 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-1906 in Idiopathic Pulmonary Fibrosis: NCT05722964 Clinical Landscape Report 2026
15 October 2026
NCT05722964 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zalfermin in Metabolic Dysfunction Associated Steatohepatitis: NCT05727644 Clinical Landscape Report 2026
15 October 2026
NCT05727644 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Etavopivat in Anemia, Sickle Cell: NCT05725902 Clinical Landscape Report 2026
15 October 2026
NCT05725902 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.